OBJECTIVES: The objective of this work is to set a cost benefit analysis of the use of fibrin sealant patch as supportive treatment in surgery for improvement of hemostasis, to promote tissue sealing and for suture support in surgery in those cases where standard techniques are not adequate. METHODS: Efficacy data were obtained from a systematic literature review. The analysis of the costs of hospitalization was conducted on the basis of detection of actual costs, observed from the point of view of the hospital. We performed a cost benefit analysis of the use of fibrin sealant patch valuing the hospitalization and the consequent use of resources. The results of the economic evaluation were subjected to sensitivity analysis, building a stochastic simulation with 1000 repetitions within a normal distribution. RESULTS: In the group of patients treated with fibrin sealant patch it was observed the decrease of the duration of hospitalization vs. the group of patients treated with standard techniques: on average 2.66 days, within a range between 0.55 and 11.80 days. The cost per day of hospitalization was estimated at Euro 206.00: this led to a saving in terms of lower costs for the hospital, quantifiable in 549 Euro, from a minimum of 103 Euro and a maximum of 2431 Euro. The use of fibrin sealant patch led then an average savings of about 304.00 Euro per patient with a cost-benefit ratio equal to 2.24 (min. 00.42 - max. 9.93). Overall the results of the sensitivity statistics confirm a lower length of stay associated with fibrin sealant patch than standard care. CONCLUSIONS: The analysis shows the positive role of fibrin sealant patch  as supportive treatment in surgery where standard techniques are revealed not adequate, with decreased postoperative complications, shorter hospital stays and reducing hospital costs.